KLRK1 and leukemia: Notably, NRAS G12D and FLT3 N676K mutations induced immune-related transcriptional programs, leading to increased expression of NKG2D ligands on leukemia cells, making them more susceptible to NKG2D-CAR T cell-mediated killing.